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Ideal Cardiovascular Health and Incident Cardiovascular Disease:
Heterogeneity Across Event Subtypes and Mediating Effect of Blood
Biomarkers: The PRIME Study
Bamba Gaye, PhD;* Muriel Tafﬂet, MSc;* Dominique Arveiler, MD; Michele Montaye, MD; Aline Wagner, MD; Jean-Bernard Ruidavets, MD;
Frank Kee, MD, PhD; Alun Evans, MD, PhD; Philippe Amouyel, MD, PhD; Jean Ferrieres, MD, MPH; Jean-Philippe Empana, MD, PhD
Background-—The aim of this study was to investigate whether the association between baseline cardiovascular health (CVH) and
incident cardiovascular disease differs according to coronary heart disease (CHD) and stroke subtypes, and to assess the
mediating effect of inﬂammatory and hemostatic blood biomarkers.
Methods and Results-—The association of ideal CVHwith outcomes was derived in 9312middle-agedmen fromNorthern Ireland and
France (whole cohort) inmultivariable Cox proportional hazards regression analysis. Themediating effect of baseline inﬂammatory and
hemostatic blood biomarkers was evaluated in a case–control study nested within the cohort after 10 years of follow-up. After a
median follow-up of 10 years, 614 ﬁrst CHD events and 117 ﬁrst stroke events were adjudicated. Comparedwith thosewith poor CVH,
those with an ideal CVH proﬁle at baseline had a 72% lower risk of CHD (hazard ratio=0.28; 95% conﬁdence interval, 0.17; 0.46) and a
76% lower risk of stroke (hazard ratio =0.24; 95% conﬁdence interval, 0.06; 0.98). The magnitude of the risk reductions was similar for
incident angina and myocardial infarction, but was lower for ischemic stroke. In the controls, the mean concentrations of high-
sensitivity C-reactive protein, IL-6, and ﬁbrinogen decreased with higher CVH status. Furthermore, the association of behavioral CVH
with incident CHD was partly mediated by high-sensitivity C-reactive protein (16.69%), IL-6 (8.52%), and ﬁbrinogen (7.30%)
Conclusions-—Our study shows no clear heterogeneity in the association of baseline CVH with the main subtypes of cardiovascular
disease. This supports a universal promotion of ideal CVH for all cardiovascular disease subtypes. Furthermore, our mediation
analysis suggests that the lower risk of CHD associated with ideal CVH is partly mediated by lower inﬂammatory and hemostatic
blood biomarkers. ( J Am Heart Assoc. 2017;6:e006389. DOI: 10.1161/JAHA.117.006389.)
Key Words: blood biomarkers • cardiovascular disease prevention • subtypes of cardiovascular diseases
P rimordial prevention deﬁned as the prevention of riskfactor occurrence has been recently re-emphasized by
the American Heart Association (AHA) to further strengthen
the primary prevention of cardiovascular disease (CVD).1 To
this end, the AHA has developed a simpliﬁed 7-item tool
including health behaviors (body mass index, smoking status,
diet, and physical activity) and health factors (blood pressure,
blood cholesterol, and glycemia) to deﬁne an ideal cardiovas-
cular health (CVH).1 Accordingly, several cohort studies have
reported substantial risk reductions in mortality and incident
CVD in subjects with an ideal compared with subjects with poor
CVH.2–6 Most of these studies, however, were conducted in the
United States2,3 and in China,4,5 whereas only 1 study
investigated a European population.6 Furthermore, although
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atherosclerosis is the process underlying most CVD events,
some atherosclerotic risk factors included in CVH have been
shown to be differentially associated with future CVD sub-
types.7–12 For instance, smoking status has demonstrated
highly heterogeneous association across 12 speciﬁc ﬁrst
manifestations of CVD.11 It might therefore be hypothesized
that the association between CVH and CVD differs according to
subtypes. First, this question may raise the issue of whether or
not the promotion of ideal CVH should be CVD disease speciﬁc
or should concern all CVD subtypes. Second, any heterogeneity
across CVD subtypes would imply the search for additional and
more speciﬁc etiological metrics. Furthermore, studies on the
possible pathways underlying the association betweenCVH and
outcomes are scarce. Inﬂammatory and hemostatic blood
biomarkers such as higher CRP (C-reactive protein), IL-6, and
ﬁbrinogen have been robustly associated with CHD or stroke
and might represent relevant mediating factors to explore.13–16
So far, only the Framingham study has explored the possible
role of blood biomarkers in the associations between ideal CVH
and outcomes.17 This analysis did not include IL-6, which is a
strong predictor of CVD. Therefore, how much the association
of CVH with CHD and stroke is mediated by IL-6 is unknown.
Our goalswere3-fold: (1) toquantify theassociationbetween
CVH and incident CHD and stroke in a Northern Irish and French
Europeanpopulationat contrasting riskofCHDandstroke; (2) to
assess for potential heterogeneity of this association across
CHD and stroke subtypes and between CHD and stroke events;
and (3) to explore the mediating effect of a panel of key
inﬂammatory and hemostatic blood biomarkers.
Methods
The PRIME (Prospective Epidemiological Study of Myocardial
Infarction) study is a prospective multicenter cohort of 10,602
middle-aged men (50–59 years) recruited in the framework of
WHO MONICA (Monitoring Trends and Determinants in
Cardiovascular Disease) centers in Lille (North France),
Strasbourg (North-East France), Toulouse (South France),
and Belfast (Northern Ireland) between 1991 and 1993.18 The
ethics committee of the Kremlin Bice^tre hospital approved the
study and men signed a statement of informed consent.
As will be seen, heterogeneity across subtypes was assessed
in the whole PRIME study while the mediating effect of
inﬂammatory and hemostatic blood biomarkers was studied in
a case–control study nested within the PRIME study. However,
because ﬁbrinogen was also available in the whole cohort, its
inﬂuence was investigated in the whole PRIME study as well.
Baseline Examination
A full description of clinical and laboratory measurements has
been already published18 and is summarized in Data S1.
Cardiovascular health
Each of the 7 metrics was categorized as poor, intermediate, or
ideal using the AHA criteria.1 Their deﬁnitions together with the
food frequency and physical activity questionnaires19,20 are
detailed in the supplemental material. According to the AHA, an
ideal CVH is deﬁned by the simultaneous presence of the 7
metrics at the ideal level and the absence of any previous CVD.1
As only 1 participant met these requirements in the present
study (see Results section), and consistently with previous
studies, subjects having 0 to 2, 3 to 4, and 5 to 7 metrics at the
ideal level were referred to as having poor, intermediate, and
ideal global CVH, respectively.3,17,21 Those with 0 to 1, 2 or 3 to
4 ideal behavioral metrics were deﬁned as having poor,
intermediate, or ideal behavioral CVH. Those with 0 to 1, 2 or
3 ideal health factors were deﬁned as having poor, intermedi-
ate, or ideal health factor CVH.21 By adding each individual
metric level (scored 0, 1, and 2 for poor, intermediate, or ideal
level), we also calculated a score for global CVH that ranged
from 0 (all poor metrics) to 14 (all ideal metrics).
Follow-up and event deﬁnitions
The procedures of annual follow-up and adjudication of coronary
heart disease and stroke events have been previously pub-
lished.9,22 Brieﬂy, participants were contacted annually by letter,
over 10 years, and asked to complete a clinical event
Clinical Perspective
What Is New?
• This is the ﬁrst study addressing the possible heterogeneity
in the association of cardiovascular health (CVH) status with
incident coronary heart disease (CHD) and stroke subtypes.
• Risk reductions were of comparable magnitude between
CHD and stroke, and across CHD subtypes and across
stroke subtypes, indicating that there was no clear hetero-
geneity in the association of baseline CVH status with 10-
year risk of cardiovascular disease, whatever types of
cardiovascular disease.
• Our mediation analysis suggests that the lower risk of CHD
associated with ideal CVH was partly mediated by lower
inﬂammatory (high-sensitivity C-reactive protein and IL-6)
and hemostatic (ﬁbrinogen) blood biomarkers.
What Are the Clinical Implications?
• The results of this study support a universal promotion of
ideal CVH for preventing all types of cardiovascular disease.
• Furthermore, our study results provide some insights
regarding the possible pathways underlying the CHD risk
reduction associated with CVH.
DOI: 10.1161/JAHA.117.006389 Journal of the American Heart Association 2
Cardiovascular Health, CVD Pathways and Subtypes Gaye et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
arch 13, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
questionnaire. For all men reporting a possible event, clinical
information was sought directly from the hospital or general
practitioner records. CHD and stroke were validated by 2
independent adjudication committees. CHD events (stable and
unstable angina,myocardial infarction, and coronary death) were
deﬁned as previously described using clinical, biological, stress-
test, scintigraphic, or angiographic criteria.22 Stroke (ischemic
and hemorrhagic strokes) was deﬁned according to WHO
MONICA criteria, as a new focal or global neurological deﬁcit
with a rapid onset and of vascular origin, persisting formore than
24 hours. Transient ischemic attacks and strokes caused by a
blood disease, a cerebral tumor or metastasis, or secondary to a
trauma, were not considered by the stroke medical committee.
Nested case–control study and blood biomarkers
measurements
The blood biomarkers analysis was conducted in the context
of a case–control study nested within the PRIME cohort after
10 years of follow-up.23 Given that there were only 2 incident
ischemic stroke events among men with intermediate or ideal
CVH, we only considered CHD cases for analysis. Therefore,
the present case–control study involves 617 CHD cases and
1234 matched controls (2 controls per case) with available
baseline blood biomarkers. Matched controls were study
participants recruited in the same center on the same day
(3 days), of the same age (3 years) as the corresponding
case, and who were free of CHD at the time of the index date.
From the existing panel of inﬂammatory and hemostatic
blood biomarkers measured at baseline in PRIME, we only
selected those that have been previously shown to be
signiﬁcantly associated with future CHD over 10 years in
PRIME, and for which robust evidence exists in the literature.
These include inﬂammatory blood biomarkers (hs-CRP [high-
sensitivity C-reactive protein]) and a hemostatic blood
biomarker (ﬁbrinogen).13–16 Blood biomarkers were assessed
on frozen samples as previously indicated.24 Multiplex
bioassays were conducted using measurement kits from the
following manufacturers: Indicia Biotechnology (Oullins,
PRIME
N =10602
Free of CVD at baseline
N= 9711
Stroke history N=68 
CHD history N=814 
Stroke and CHD history N=9
Eligible population
N= 9345 
Missing covariates* N = 366 
(living alone (51), marital status (2),
family history of CHD (59),
fibrinogen (257) )
Behavioural
Cardiovascular Health
N=9323
Global
Cardiovascular Health
N=9312
Health factors
N=9288
N=33‡N=57† N=22§
Diabetes mellitus n=9345
Cholesterol n=9300
Blood pressure n=9332
Smoking n=9345
BMI n=9344
Diet n=9345
Physical activity n=9320
Score of  
Cardiovascular Health
N=9261
N=84||
Figure 1. Study ﬂowchart of the whole PRIME cohort. *Missing covariates do not add up to 369 because 1 subject had missing data for
marital status and living alone, simultaneously and 2 subjects had missing data for ﬁbrinogen and family history of CHD, simultaneously.
†Subjects with missing data for diabetes mellitus, cholesterol, or blood pressure. ‡Subjects with missing data for at least 1 CVH metric and the
information on the other metrics was not sufﬁcient to assign a CVH status. §Subjects with missing data for smoking, BMI, diet, or physical
activity. ||Subjects with missing data for at least 1 CVH metric. BMI indicates body mass index; CHD, coronary heart disease; CVD,
cardiovascular disease; CVH, cardiovascular health; PRIME, Prospective Epidemiological Study of Myocardial Infarction.
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France) for hs-CRP (LOB1707). IL-6 was measured by high-
sensitivity ELISA (BMS213HS; Bender MedSystems, Vienna,
Austria).
Statistical Analysis
Heterogeneity across event subtypes: whole cohort
The baseline characteristics by global CVH status were
compared using analysis of variance or Kruskal-Wallis test or
Pearson v2 tests where appropriate. Unadjusted survival free of
all-cause mortality and of CHD and stroke events by global CVH
status were plotted on Kaplan–Meier curves and compared
using the log-rank test. Hazard ratios (HR) and 95% conﬁdence
intervals (CI) of baseline intermediate and ideal CVH status
(according to global, behavioral, and health factor) for all-cause
mortality, and for CHD, stroke, and their respective subtypes
were estimated in a separate Cox proportional hazards
regression model, using baseline poor CVH as the reference
exposure category. Follow-up was censored at the date of ﬁrst
event, at the date of death, or at the end of follow-up, whichever
came ﬁrst. HRs were adjusted for age, study center, education,
Table 1. Baseline Characteristics According to Global CVH Status in the Whole PRIME Study
Global CVH
P ValuePoor (N=3699) Intermediate (N=4957) Ideal (N=656)
Study center*
Belfast 946 (25.6) 1190 (24.0) 156 (23.8) <0.0001
Strasbourg 925 (25.0) 1296 (26.1) 117 (17.8)
Toulouse 754 (20.4) 1350 (27.2) 267 (40.7)
Lille 1074 (29.0) 1121 (22.6) 116 (17.7)
Age† 55.0 (2.9) 54.8 (2.9) 54.4 (2.8) <0.0001
Family history of CHD* 424 (11.5) 478 (9.6) 61 (9.3) 0.0151
Social status*
High 1074 (29.0) 1405 (28.3) 221 (33.7) 0.0006
Middle 1884 (50.9) 2639 (53.2) 344 (52.4)
Low 741 (20.0) 913 (18.4) 91 (13.9)
Secondary level diploma or more* 2297 (62.1) 3214 (64.8) 437 (66.6) 0.0101
Living alone* 322 (8.7) 329 (6.6) 56 (8.5) 0.001
Marital status*
Single 198 (5.4) 232 (4.7) 29 (4.4) 0.0165
Cohabiting 3186 (86.1) 4383 (88.4) 564 (86.0)
Widowed 85 (2.3) 92 (1.9) 13 (2.0)
Separated 230 (6.2) 250 (5.0) 50 (7.6)
Number of min per wk of moderate activity‡ 0.0 (0.0–60.0) 40.0 (0.0–270) 138 (0.0–330) <0.0001
Number of min per wk of vigorous activity‡ 0.0 (0.0–0.0) 0.0 (0.0–175) 71.0 (0.0–240) <0.0001
Number of kilocalories per wk of alcohol‡ 1515 (472–2852) 1191 (298–2312) 741 (140–1612) <0.0001
Number of fruits and vegetables per d‡ 2.3 (1.5–3.3) 2.6 (1.7–3.6) 3.0 (2.0–4.1) <0.0001
BMI, kg/m²† 28.0 (3.3) 25.9 (3.2) 23.5 (2.2) <0.0001
Systolic blood pressure, mm Hg† 139 (18.4) 131 (18.0) 117 (14.3) <0.0001
Treatment for diabetes mellitus* 559 (15.1) 186 (3.8) 7 (1.1) <0.0001
Blood pressure–lowering drugs* 660 (17.9) 559 (11.3) 24 (3.7) <0.0001
Glucose-lowering drugs* 164 (4.4) 49 (1.0) 0 (0.0) <0.0001
Lipid-lowering drugs* 488 (13.2) 360 (7.3) 15 (2.3) <0.0001
Fibrinogen, g/L‡ 3.17 (2.74–3.76) 3.04 (2.66–3.57) 2.98 (2.60–3.50) <0.0001
Results are n (%)* or mean (SD)†, or median (interquartile range)‡ where appropriate. P values are from Pearson v2 test, or analysis of variance, or Kruskal–Wallis test where appropriate.
BMI indicates body mass index; CHD, coronary heart disease; CVH, cardiovascular health status; PRIME, Prospective Epidemiological Study of Myocardial Infarction.
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social status, living alone and marital status, family history of
CHD, and ﬁbrinogen (which was available for the whole cohort).
The HRs for CHD and stroke, and across CHD subtypes (angina,
myocardial infarction, and coronary death) and stroke subtypes
(ischemic versus nonischemic), were compared by the visual
inspection of the HRs and their 95% CIs (no formal statistical
test for comparison) to assess heterogeneity. The proportion-
ality assumption of Cox regression analysis was veriﬁed
graphically by plotting Schoenfeld residuals and further by
adding an interaction with time to our Cox model and checking
whether it signiﬁcantly improves our model.
In sensitivity analysis, the possible competing effect of
death was evaluated using the Fine and Gray method, with
subdistribution HR of ideal and intermediate CVH estimated
for CHD and stroke outcomes.25 The HRs per 1-point
increment in the score of global cardiovascular health were
also calculated.
Blood biomarkers mediating effect: nested case–
control study
In the nested case–control study, we ﬁrst compared the mean
concentrations of each blood biomarker across CVH status
among the controls in separate linear regression analysis
adjusted for age and study centers. Thereafter, blood
biomarkers that were signiﬁcantly associated with CVH status
(in the controls) were added separately into a multivariable
conditional logistic regression model. First, the relative
attenuation (%) of the regression coefﬁcient estimates of
CVH status for CHD upon adjustment for a given blood
biomarker was calculated (as the difference between the
regression coefﬁcient before and after adjustment for the
blood biomarker relative to the regression coefﬁcient before
adjustment for the blood biomarker). Second, we conducted a
mediation analysis for each blood biomarker by evaluating the
direct and the indirect effect of CVH status on incident CHD
using an extension of the Baron and Kenny method developed
by Valeri et al.26
All statistical analyses were 2-tailed and used a P<0.05 to
mean statistically signiﬁcant associations. SAS software
version 9.4 (SAS Institute Inc, Cary, NC) was used for all
analyses.
Results
Whole Cohort Analysis
Study population
As shown in the study ﬂowchart (Figure 1), the study
population cohort comprises 9312 men free of personal
history of CVD including 2292 from Belfast (Northern Ireland)
and 7020 from France.
Baseline characteristics by CVH status
At baseline, only 1 participant had the 7 metrics at the ideal
level, 96 had 6 metrics at the ideal level, and 557 had 5
metrics at the ideal level, respectively. Altogether, 7.1% of the
participants had at least 5 metrics at the ideal level and were
referred to as being in ideal CVH. There was a north–south
contrast in the distribution of CVH as the prevalence of ideal
CVH was 5.0% for Strasbourg and Lille (North and North-East
France), 6.8% for Belfast (Northern Ireland), and 11.3% for
Toulouse (south France) (P<0.001). Conversely, 39.8% of the
population had up to 2 metrics at the ideal level and were
referred to as being in poor CVH (46.5% for Lille, 41.3% for
Belfast, 39.6% for Strasbourg, and 31.8% for Toulouse,
P<0.001). As shown in Table 1, in general, the burden of
sociodemographic, cardiovascular risk factors and the con-
centration of ﬁbrinogen decreased with increasing CVH
status. Ideal diet was the least prevalent metric (1.4%) while
A B C
Figure 2. Free-of-event Kaplan–Meier curves of ﬁrst coronary heart disease and stroke by baseline global cardiovascular health status
(N=9312) in the whole PRIME cohort. A, Coronary heart disease+stroke. B, Coronary heart disease. C, Stroke. Cardiovascular health
status: Poor: 0 to 2 ideal metrics; Intermediate: 3 to 4 ideal metrics; Ideal: 5 to 7 ideal metrics. PRIME indicates Prospective
Epidemiological Study of Myocardial Infarction.
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nondiabetic status was the most prevalent (91.2%) (not
shown).
HRs of baseline cardiovascular health status for ﬁrst
clinical events
After a median duration of follow-up of 10 years, we observed
731 incident events: 614 CHD including 248 myocardial
infarction, 208 stable angina, 130 unstable angina, and 28
coronary deaths; 117 stroke including 94 ischemic and 23
nonischemic strokes.
As shown in Figure 2A through 2C, the crude incidence
rates of CHD and stroke (either combined or studied
separately) progressively decreased with higher baseline
CVH status. The multivariable HRs of CHD and stroke
associated with global, behavioral, and health factor CVH
are presented in Table 2. In particular, analysis by event
subtypes shows a 72% lower risk of CHD (HR=0.28; 95% CI,
0.17; 0.46) and a 76% lower risk of stroke (HR=0.24; 95% CI,
0.06; 0.98) in men with ideal compared with poor CVH at
baseline, suggesting no difference between CHD and stroke.
Also, the risk of CHD (HR=0.80; 95% CI, 0.77–0.83) and
stroke (HR=0.80; 95% CI, 0.74–0.89) decreased similarly by
20% per 1-point increment of the score of global CVH in fully
adjusted analysis. Furthermore, analysis by event subtype
indicates fairly consistent relative risk reduction across CHD
subtypes, whereas relative risk reductions were of lower
magnitude for ischemic and nonischemic strokes (Figure 3).
Of note, during follow-up, 414 men had died (see the
Kaplan–Meier curves of mortality by CVH status in Figure S1),
and in multivariable analysis, the HRs of all-cause mortality for
intermediate and ideal CVH versus poor CVH were, respec-
tively, 0.77 (95% CI, 0.65–0.92) and 0.65 (95% CI, 0.42–0.99).
However, the association between global CVH and CHD and
stroke did not change when competing risk by death was
taken into account (Table S1). Furthermore, association
between CVH and CHD and stroke combined was consistent
across study centers, and no signiﬁcant interaction was
detected (Table S2).
Nested case–control study: Mediating effect of blood
biomarkers
This analysis is based on 617 ﬁrst CHD cases and 1234
matched controls (2 controls per case). Among the controls,
the mean concentrations of hs-CRP, IL-6 (inﬂammatory blood
biomarkers), and of ﬁbrinogen (hemostatic blood biomarker)
decreased with increasing CVH status (Table 3). This was
observed essentially with the behavioral CVH. Blood biomark-
ers concentrations by level of each metric are given in
Table S3. The multivariable HR of intermediate and ideal CVH
for CHD were slightly attenuated upon adjustment for each
blood biomarker (Table 4 and Table S4). This also appliedTa
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when looking at each metric separately. Stronger relative
attenuation was observed with behavioral CVH after adjust-
ment for hs-CRP (13.28%), IL-6 (8.13%), and ﬁbrinogen
(10.73%), respectively. Accordingly, mediation analysis for
behavioral CVH (Table 4) indicates statistically signiﬁcant
indirect effect (ie, mediating effect) of hs-CRP (16.69%), IL-6
(8.52%), and ﬁbrinogen (7.30%), respectively.
Discussion
In this multicenter community-based prospective cohort of
men aged between 50 and 59, we observed a 72% lower risk
of CHD and a 76% lower risk of stroke in men with ideal
compared with poor CVH over a median follow-up of 10 years.
These risk reductions were consistent for the behavioral and
the health factor CVH. There was no heterogeneity across
main CHD and main stroke phenotypes, between CHD and
stroke, or between Northern Ireland and France. Finally, lower
concentrations of hs-CRP, IL-6, and ﬁbrinogen partly mediated
the lower risk of CHD associated with intermediate and ideal
CVH, especially behavioral CVH.
The 7% of middle-aged men in ideal CVH is consistent with
rates reported in the literature.3,27,28 We did observe some
heterogeneity in the prevalence of ideal CVH across study
centers. In accordance with the North–South gradient of CVD
incidence, the highest rates of ideal CVH were observed in
Toulouse (South-East France), whereas the lowest rates were
observed in Belfast (Northern Ireland), Strasbourg (North-East
France), and Lille (North of France).
Previous studies relating ideal CVH with future CVD were
mainly conducted in the United States and in China.2–5 So far,
only 1 study, the EPIC (European Prospective Investigation
into Cancer and Nutrition) Norfolk study, was conducted in a
European population.6 In this study, a 97% and 84% lower risk
Figure 3. Multivariable hazard ratios of baseline global cardiovascular health status for main coronary
heart disease (CHD) and stroke subtypes in the whole PRIME (Prospective Epidemiological Study of
Myocardial Infarction) cohort. Hazards ratios (HR) and 95% conﬁdence intervals (CI) were estimated in
separate Cox proportional hazards regression model using Poor status as the reference exposure and were
adjusted for age, study center, family history of CHD, education, social status, living alone status, cohabiting
status, and ﬁbrinogen. Cardiovascular health status: Poor: 0 to 2 ideal metrics; Intermediate: 3 to 4 ideal
metrics; Ideal: 5 to 7 ideal metrics.
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of CHD and stroke was found in subjects with ideal compared
with poor CVH, respectively. These results are consistent with
our ﬁndings, although the magnitudes of these risk reductions
are apparently higher than ours (97% versus 72% risk
reduction for CHD, and 84% versus 39% for stroke). This is
likely because of the fact that they contrasted extreme
categories of CVH (ie, subjects with 6 or 7 ideal metrics
versus subjects with at best 1 metric at the ideal level),
whereas in our study, we compared men with 5 to 7 ideal
metrics versus men with 0 to 2 ideal metrics, respectively. In
the EPIC Norfolk study, however, 61% (n=15 000) of the
participants were excluded from the analysis because of
missing covariates, possibly giving a selective picture of the
association between CVH and outcomes.
To the best of our knowledge, this is the ﬁrst study
addressing the possible heterogeneity in the association of
CVH status with incident CHD and stroke subtypes. The
rationale of our approach is that some risk factors that are
part of the CVH construct including smoking status, type 2
diabetes mellitus, and blood pressure have demonstrated
heterogeneous associations across ﬁrst manifestations of
CVD.7–12 For instance, in PRIME, we previously showed
differential associations of lipids with incident CHD as
compared with stroke over 10 years, and heterogeneous
associations of traditional risk factors with incident stable
angina as compared with acute coronary syndrome.9,10 More
recently, data from the CALIBER (Cardiovascular disease
research using linked bespoke studies and electronic health
records) study based on nearly 2 million participants from
primary care practices in England reported a highly hetero-
geneous association of smoking status with lifetime risk for
12 ﬁrst manifestations of CVD.11 In our study, however, we
did not observe clear evidence for heterogeneity in the
association of CVH between CHD and stroke, or across CHD
and stroke subtypes. This supports the uniform application of
the AHA ideal CVH tool for health promotion for all subtypes
of CVD, at least for CHD and for stroke. It should be noted,
however, that coronary death and nonischemic stroke were
particularly rare, so that the related HRs should be interpreted
with caution. Furthermore, a lifetime risk approach8 may offer
a more powerful way than the present analysis based on a 10-
year risk window to detect heterogeneity across subtypes. An
additional source of heterogeneity might have been expected
across PRIME study centers, given established differences in
lifestyle risk factors including diet20 and alcohol consump-
tion.29 However, the association between CVH and outcomes
(CHD and stroke combined) operated equally across study
centers, and between France and Northern Ireland. This
emphasizes the universal promotion of ideal CVH across
populations with different risk factors proﬁle.
So far, only the Framingham study has explored how much
novel blood biomarkers could contribute to the associations
between ideal CVH and outcomes.17 In that study, the relative
attenuation of the HRs was 33% upon simultaneous
Table 3. Baseline Concentrations of Circulating Blood Biomarkers in Controls by Baseline CVH Status in the Nested Case–Control
Study
CVH Status N
Inﬂammatory Blood Biomarkers Hemostatic Blood Biomarker
Hs-CRP (mg/L) IL-6 (pg/mL) Fibrinogen (g/L)
Global
Poor 472 2.68 (1.42–4.92) 0.29 (0–0.82) 3.21 (2.79–3.77)
Intermediate 632 2.09 (1.04–4.49) 0.22 (0–0.60) 3.10 (2.72–3.64)
Ideal 86 1.61 (0.86–2.98) 0.21 (0–0.52) 2.99 (2.64–3.37)
P for trend <0.0001 0.08 0.006
Behavioral
Poor 616 2.74 (1.39–4.94) 0.31 (0–0.75) 3.20 (2.81–3.83)
Intermediate 441 2.05 (1.03–4.38) 0.21 (0–0.62) 3.06 (2.69–3.61)
Ideal 132 1.55 (0.82–2.81) 0.18 (0–0.44) 3.06 (2.64–3.50)
P for trend <0.0001 0.02 0.005
Health factor
Poor 757 2.41 (1.24–4.62) 0.23 (0–0.70) 3.14 (2.74–3.68)
Intermediate 367 2.25 (1.10–4.74) 0.29 (0–0.62) 3.11 (2.70–3.68)
Ideal 64 1.71 (0.82–3.91) 0.29 (0–0.62) 3.08 (2.73–3.68)
P for trend 0.036 0.65 0.56
Results are medians (interquartile range)—Comparisons and P values for trend derived from linear regression analysis on log-transformed blood biomarkers and were adjusted for age and
study center. Blood biomarkers concentrations were obtained on fasting baseline plasma samples. CVH indicates cardiovascular health status; hs-CRP, high-sensitivity C-reactive protein.
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adjustment for brain natriuretic peptides, PAI-1, and growth
differentiation factor 15, and a further 20% relative attenua-
tion upon subsequent adjustment for subclinical markers of
vascular disease, yielding an almost 47% relative attenuation
when all blood biomarkers were combined in the same model.
The relative attenuations were much lower in our study and
ranged from 8.13% to 13.28% when exploring behavioral CVH.
Beyond the fact that we did not evaluate the same blood
biomarkers (except hs-CRP), these differences may also partly
be because of the fact that our study sample comprised
exclusively men, unlike the Framingham study. Indeed,
women are twice to 4 times more likely to have ideal
CVH28,30 but often have higher concentrations of inﬂamma-
tory and hemostatic blood biomarkers than men. Compared
with the Framingham study, we investigated the impact of IL-
6, which is a strong and potentially causal predictor of CVD,
and additionally provided a mediation analysis. In our study,
hs-CRP and to a lesser extent IL-6 and ﬁbrinogen had a
signiﬁcant mediating effect on the association between CVH
status and incident CHD events. These mediating effects were
relatively small in magnitude, ranging from 3.61% to 9.57%,
but were of stronger magnitude in the analysis of behavioral
CVH, ranging from 7.3% to 16.69%. Repeated measurements
of blood biomarkers could help to better quantify their
mediating effect. Additional mediating pathways should also
be explored. In a recent cross-sectional analysis, we demon-
strated signiﬁcant differences in subclinical carotid structural
and functional parameters across CVH status.31 The extent to
which these alterations contribute to the association between
ideal CVH and CVD needs to be investigated in future
prospective analysis.
We acknowledge the following limitations. Generalization
to women and other age groups cannot be made. CVH status
was evaluated in the early 1990s, when statins were not
commonly prescribed and when the distribution of risk
factors, especially with respect to smoking, differed from
what we observe currently. This may affect the prevalence
estimates but not the associations under investigation. As in
many studies, the deﬁnition of the diet metric was not
optimal. This might contribute to the lack of signiﬁcant
association of the diet metric with combined CHD or stroke.
We also acknowledge the incomplete deﬁnition of the
glycemic metric. By investigating treated diabetes mellitus
only, we missed undiagnosed diabetes mellitus and possibly
underestimated the association of diabetes mellitus with
outcomes. CVH was available at baseline only, so that change
Table 4. HR for First CHD of Global, Behavioral, and Health Factor CVH Status Without and With Adjustment for Inﬂammatory and
Hemostatic Blood Biomarkers in the Nested Case–Control Study
CVH Status n/N
Model 1 Model 1+hs-CRP Model 1+IL-6 Model 1+Fibrinogen
HR (CI 95%) HR (CI 95%) HR (CI 95%) HR (CI 95%)
Global 587/1777
Poor 317/789 1 1 1 1
Intermediate 254/886 0.58 (0.47–0.72) 0.58 (0.47–0.73) 0.58 (0.46–0.72) 0.60 (0.48–0.74)
Ideal 16/102 0.26 (0.15–0.47) 0.29 (0.16–0.52) 0.28 (0.16–0.50) 0.27 (0.15–0.49)
% Relative attenuation 8.09 5.50 2.80
% Mediated 9.57 4.91 3.61
Behavioral 590/1779
Poor 360/976 1 1 1 1
Intermediate 194/635 0.75 (0.60–0.93) 0.76 (0.61–0.95) 0.75 (0.60–0.93) 0.77 (0.62–0.96)
Ideal 36/168 0.46 (0.31–0.69) 0.51 (0.34–0.77) 0.49 (0.33–0.74) 0.50 (0.33–0.75)
% Relative attenuation 13.28 8.13 10.73
% Mediated 16.69 8.52 7.30
Health factor 584/1772
Poor 454/1211 1 1 1 1
Intermediate 117/484 0.49 (0.38–0.64) 0.48 (0.37–0.62) 0.45 (0.35–0.60) 0.50 (0.39–0.65)
Ideal 13/77 0.33 (0.18–0.62) 0.34 (0.18–0.63) 0.35 (0.19–0.66) 0.31 (0.17–0.59)
% Relative attenuation 2.69 5.31 5.64
% Mediated 3.85 0.03 1.27
Hazard ratios were estimated by conditional logistic regression and model M1 included age, study center and family history of CHD, education, social status, living alone status, and marital
status as covariates. Mediating effect was estimated using an extension of the Baron and Kenny method developed by Valeri et al.26 CHD indicates coronary heart disease; CI, conﬁdence
interval; CVH, cardiovascular health status; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein.
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in CVH over time could not be related to incident CVD. Finally,
we acknowledge that the AHA life 7 metrics tool is intended
to be a simple one to promote an ideal CVH, but we should
keep in mind that each of the 7 metrics may not have the
same weight regarding their association with CVD.
In summary, in this large European study of middle-aged
men, men with 5 ideal metrics or more had a substantially
lower risk of CHD and stroke as compared with those with up
to 2 metrics at the ideal level. Risk reductions were of
comparable magnitude between CHD and stroke, and across
CHD subtypes and possibly across stroke subtypes, indicating
that there was no clear heterogeneity in the association of
baseline cardiovascular health with the main subtypes of CVD.
This supports a universal promotion of ideal CVH to prevent
all types of CVD. Furthermore, these risk reductions were
partly mediated by lower concentrations of inﬂammatory (hs-
CRP and IL-6) and hemostatic (ﬁbrinogen) blood biomarkers.
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Data S1. 
Baseline examination: 
At baseline, men answered to standardized and detailed questionnaires regarding past medical 
history, demographic and socioeconomic factors, tobacco and alcohol consumption, 
psychological factors including depressive mood.1 Physical activity was assessed for the year 
preceding recruitment by means of the MONICA Optional Study of Physical Activity 
Questionnaire (MOSPA-Q) 2, while information on diet was obtained through a food frequency 
questionnaire. 3 Height and body weight were measured by nurses during physical examination 
in subjects with light clothing and no shoes. Diabetes was defined by current diet for diabetes 
or current intake of oral hypoglycemic treatment. Blood pressure was measured in a sitting 
position after 5 min of rest with the same automatic device (Spengler SP9, Spengler, Cachan, 
France).  
Blood was drawn after an overnight fast. A subset of biological measurements was performed 
in fresh plasma in the entire cohort. Plasma lipid analyses were centralized (SERLIA INSERM 
U325, Institut Pasteur de Lille, France). Total cholesterol (Total-C) and high-density 
lipoprotein cholesterol (HDL-C) were measured by enzymatic methods using commercial kits 
in an automatic analyzer (Boehringer, Mannheim, Germany). Fibrinogen was assessed at the 
Laboratory of Hemostasis of La Timone Hospital in Marseilles, France, using commercially 
available ELISAs from Diagnostica Stago (Asnières-sur-Seine, France). Aliquots of serum and 
plasma were then frozen in liquid nitrogen until analysis of biomarkers in nested case control 
studies (see corresponding paragraph). 
Cardiovascular health metric definition 
Cardiovascular health metrics were defined according to the American Heart Association 
criteria. 4 
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Behavioural metrics 
Body mass index 
Anthropometric factors were measured in subjects with light clothing and no shoes by nurses 
during physical examination. Height was measured to the nearest cm while body weight was 
determined to the nearest 200g. Body mass index (BMI) was quantified as body weight divided 
by the square of height (kg/m2). Poor, intermediate and ideal BMI were defined by values > 30 
kg/m2, between 25 and 29.9 kg/m2 and below 25 kg/m2 respectively. 
Smoking habits 
In the general self-administrated questionnaire, participants reported their current smoking 
status (never smoker/ex smoker/current smoker) and the time since smoking cessation (for ex-
smokers). Poor, intermediate and ideal smoking status corresponded to current smokers, ex-
smokers that have stopped for less than 12 months, and never smokers or ex-smokers that have 
stopped for at least 12 months respectively. 
Physical Activity 
Physical activity was assessed for the year preceding recruitment by means of the MONICA 
Optional Study of Physical Activity Questionnaire (MOSPA-Q), whose validity and reliability 
have been reported. 2 This administered questionnaire evaluated time and mean energy 
expenditure during leisure time, at work, and during walking or cycling to and from work. 
Leisure-time walking and the two activities that were most frequently performed (sport or 
others, such as gardening) were taken into account. The intensities of the activities were derived 
from the Compendium and expressed in metabolic equivalents (MET) 5. Sports comprised 
between 4 and 6 MET were considered as moderate, and sports equal or more than 6 MET as 
vigorous.  Times per week for moderate and vigorous activities considered the time spent at 
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work, way to work, leisure and sport. This time took into account the annual practice.  Ideal 
status was defined as moderate activities >=150 minutes per week, or vigorous activities > 75 
minutes per week, or combined moderate and vigorous activities>=150 minutes per week.  
Intermediate status was defined as moderate or vigorous (or combined moderate and vigorous) 
activities >=1 minute / week. Poor status was defined as no moderate or vigorous activities of 
>=1 minute/week. Subjects who reported no work no leisure and no sport activities but who 
declared having an intense physical activity at least 20 minutes one time or more per week were 
classified as intermediate status. 
Diet 
Two items of the original diet metric including fibers and sodium intake could not be computed, 
so that the diet metric was computed on 3 out of the original 5 items. A food frequency 
questionnaire allowed us to estimate the frequency of fruits, vegetables and fish consumption. 
3 A detailed questionnaire on alcohol consumption (including wine, cider, beer and spirits) 
permitted us to estimate sugar intake in alcohol and to convert it into kcal/week. Then, the item 
fruits and vegetables was considered healthy if 4.5 portions of fruits and vegetables were 
consumed per day; for the fish item, if consumed twice or more per week; for the sugar item, if 
consumed equal or less than 450 kcal/week.  
Altogether, ideal diet includes 3 healthy items, intermediate 2 healthy items and poor diet as 
having one or zero healthy items. 
Biological metrics 
Blood pressure 
Blood pressure was measured in a quiet room in the sitting position with the right arm on a desk 
at the heart level after a 5-min rest using an automatic sphygmomanometer (Spengler SP9; 
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Springler, Cachan, France). Poor, intermediate and ideal blood pressure corresponded to values 
(SBP/DBP)> =140/90 mm-Hg, values < 140/90 mm-Hg or  < 120/80 mm-Hg on medications, 
and untreated < 120/80 mm-Hg respectively.  
Blood total cholesterol 
Fasting plasma total cholesterol and HDL cholesterol levels were measured at the Central 
Laboratory in Lille by enzymatic methods using reagents from Boerhinger-Mannheim 
(Mannheim, Germany) Poor, intermediate and ideal total cholesterol corresponded to values 
>=240 mg/dL, values <240 mg/dL or  < 200 mg/dL on medications and untreated values < 200 
mg/dL respectively. 
Glucose 
In PRIME, fasting glycaemia was unavailable for the whole cohort. Thus, men were categorized 
as poor if they were on diet for diabetes or under medications for diabetes, intermediate if they 
had a history of diabetes but were no longer on medication and ideal if they had no history of 
diabetes, no diet and no medications for diabetes. 
Cardiovascular health status and cardiovascular health score 
Participants who had 0-2, 3-4 or 5-7 ideal metrics were categorized as having poor, intermediate 
or ideal global cardiovascular health, respectively. We maximized the information at hand to 
assign a CVH status when some metrics were missing. While participants with missing data on 
individual metrics were excluded from analysis for that metric, this was not the case when the 
available information on the other metrics was sufficient to assign a CVH status. For example 
a participant with 5 metrics at the ideal level and missing data on 2 metrics had the possibility 
of remaining in the analysis as he could be categorized as having an ideal global CVH. In 
contrast, in those with data on only 2 metrics, a global CVH status could not be assigned and 
the participant was excluded from analysis. This explains that the study sample size varies 
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between the metrics analysis and the analysis of CVH. (see flow chart on Figure 1). Instead, the 
score of cardiovascular health was calculated only in men with available information on the 7 
metrics.  
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Table S1. Sub distribution hazard ratios for first Coronary Heart Disease (CHD) and Stroke 
associated with cardiovascular health (CVH) status in the whole PRIME cohort taking into 
account competition by all-cause mortality.  
Global CVH status CHD+stroke CHD Stroke 
 N events                 sHR 
(95% CI) 
N events               
sHR (95% CI) 
N events           
sHR (95% CI) 
Poor (N=3699) 393                                 
1 
336                               
1 
57                         1 
Intermediate 
(N=4957) 
319                       0.61 
[0.53-0.71] 
261                    0.58 
[0.49-0.68] 
58                  0.84 
[0.58-1.21] 
Ideal (N=656) 19                         0.28 
[0.18-0.44] 
17                      0.29 
[0.18-0.47]     
2                    0.24 
[0.06-0.99] 
Sub distribution HR (sHR) of ideal and intermediate CVH for CHD and stroke were estimated 
using the Fine and Gray method 6  
and were adjusted for age, study centre, family history of CHD, education, social status, living 
alone, marital status, and fibrinogen. 
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Table S2. Hazard ratios for first Coronary Heart Disease or Stroke associated with 
cardiovascular health (CVH) status stratified by study centre in the whole PRIME cohort 
  Belfast Strasbourg Lille Toulouse 
CVH Component Status HR [CI95%] HR [CI95%] HR [CI95%] HR [CI95%] 
Global Poor 1 1 1 1 
 Intermediate 0.56 [0.43-0.72] 0.65 [0.47-0.90] 0.64 [0.46-0.88] 0.66 [0.48-0.90] 
 Ideal 0.26 [0.12-0.59] 0.41 [0.15-1.12] 0.21 [0.05-0.85] 0.28 [0.13-0.61] 
Behavioural Poor 1 1 1 1 
 Intermediate 0.66 [0.49-0.87] 0.75 [0.53-1.05] 0.86 [0.62-1.2] 0.67 [0.48-0.93] 
 Ideal 0.47 [0.27-0.83] 0.77 [0.43-1.38] 0.26 [0.1-0.63] 0.56 [0.33-0.96] 
Health factor Poor 1 1 1 1 
 Intermediate 0.60 [0.45-0.81] 0.66 [0.44-1] 0.54 [0.35-0.84] 0.54 [0.38-0.78] 
 Ideal 0.36 [0.16-0.8] - - 0.66 [0.35-1.27] 
* p for interaction between study centres and CVH status; Hazards ratios (HR) are adjusted 
for age, family history of CHD, education, social status, living alone status, marital status, and 
fibrinogen. CVH stands for cardiovascular health status 
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Table S3. Baseline concentrations of blood biomarkers in controls by baseline cardiovascular 
health metrics in the case control study nested within the PRIME cohort. 
 
 
N Inflammatory blood biomarkers 
Haemostatic blood 
biomarker 
Metrics 
 
N Hs-CRP (mg/L) IL6 (pg/mL) fibrinogen (g/L) 
Smoking Poor 316 2.67 (1.43-5.69) 0.37 (0.05-0.83) 3.28 (2.82-3.84) 
 Intermediate 42 2.98 (1.03-4.64) 0.32 (0-0.8) 3.21 (2.9-3.78) 
 Ideal 808 2.14 (1.09-4.35) 0.21 (0-0.59) 3.09 (2.69-3.64) 
 
P for trend  <0.0001 <0.0001 0.002 
Body mass 
Index 
Poor 143 3.59 (2.04-5.67) 0.41 (0.05-0.82) 3.23 (2.82-3.72) 
 Intermediate 653 2.44 (1.28-4.76) 0.23 (0-0.68) 3.11 (2.73-3.68) 
 Ideal 370 1.77 (0.82-3.74) 0.21 (0-0.61) 3.09 (2.71-3.64) 
 
P for trend  <0.0001 0.07 0.21 
Physical 
Activity 
Poor 380 2.63 (1.32-4.89) 0.32 (0-0.81) 3.21 (2.83-3.87) 
 Intermediate 240 2.25 (1.06-4.6) 0.14 (0-0.48) 3.1 (2.71-3.64) 
 Ideal 542 2.07 (1.1-4.51) 0.25 (0-0.64) 
3.06 (2.69-3.61) 
 P for trend  0.12 0.89 0.05 
Healthy 
Diet 
Poor 1019 2.36 (1.15-4.74) 0.25 (0-0.68) 3.11 (2.73-3.68) 
 Intermediate 135 2.2 (1.16-4.42) 0.21 (0-0.68) 3.11 (2.73-3.69) 
 Ideal 12 2.27 (1.51-2.98) 0.17 (0-0.62) 3.14 (2.45-3.69) 
 
P for trend  0.69 0.97 0.85 
Diabetes Poor 
32 
3.55 (2.31-6.79) 0.37 (0-1.15) 3.25 (2.64-3.76) 
 Intermediate 56 2.06 (0.98-4.3) 0.26 (0-1) 3 (2.63-3.4) 
 Ideal 1078 2.29 (1.15-4.59) 0.24 (0-0.64) 3.13 (2.75-3.68) 
 P for trend  0.03 0.81 0.53 
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Fasting 
Total 
Cholesterol 
Poor 347 2.44 (1.32-4.77) 0.29 (0-0.75) 3.22 (2.83-3.76) 
 Intermediate 519 
2.15 (1.11-4.37) 
0.2 (0-0.57) 3.11 (2.72-3.64) 
 Ideal 295 2.35 (1.09-4.93) 0.31 (0-0.71) 3.08 (2.71-3.68) 
 P for trend  0.11 0.92 0.20 
Blood 
Pressure 
Poor 467 2.74 (1.49-5.11) 0.31 (0-0.78) 3.1 (2.78-3.68) 
 Intermediate 477 2.11 (1.09-3.92) 0.22 (0-0.64) 3.14 (2.71-3.64) 
 Ideal 222 1.94 (0.95-4.25) 0.22 (0-0.56) 3.13 (2.73-3.68) 
 P for trend  <0.0001 0.016 0.88 
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Table S4. Hazard ratios for first coronary heart disease associated with global cardiovascular health before and after adjustment for inflammatory 
and haemostatic blood biomarkers in the case control study nested within the PRIME cohort  
  CVH status  
Per 1 unit 
increase of Log-
transformed 
blood biomarker  
 Poor Intermediate Ideal  
n/N=587/1777 317/789 254/886 16/102  
Model 1 1 0.58 [0.47-0.72] 0.26 [0.15-0.47]  
Model 1+hs-CRP 1 0.58 [0.47-0.73] 0.29 [0.16-0.52] 1.05 [1.02-1.08] 
Model 1+IL-6 1 0.58 [0.46-0.72] 0.28 [0.16-0.50] 1.07 [1.02-1.11] 
Model 1+Fibrinogen 1 0.60 [0.48-0.74] 0.27 [0.15-0.49] 2.11 [1.38-3.25] 
 
Hazard ratios and 95% confidence intervals (CI) were estimated in separate conditional logistic regression analysis that accounted for the  
matching variables and using Poor status as the reference exposure. Model 1 includes family history of CHD, education, social status,  
living alone status and marital status as covariates.
 by guest on M
arch 13, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Figure S1. Free of all-cause mortality Kaplan-Meier curves by baseline cardiovascular health 
status in the whole PRIME cohort (N=9312). 
 
Cardiovascular health status: Poor: 0 to 2 ideal metrics; Intermediate: 3-4 ideal metrics; 
Ideal: 5 to 7 ideal metrics  
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